FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175514092> ?p ?o ?g. }

• W3175514092 endingPage "100205" @default.
• W3175514092 startingPage "100205" @default.
• W3175514092 abstract "IntroductionWe retrospectively evaluated outcomes in patients with programmed death-ligand 1 (PD-L1)–positive non–small-cell lung cancer (NSCLC) to determine whether baseline (i.e., at study enrollment) brain metastases were associated with the efficacy of pembrolizumab versus chemotherapy.MethodsWe pooled data for patients with previously treated or untreated PD-L1‒positive (tumor proportion score [TPS], ≥1%) advanced or metastatic NSCLC in KEYNOTE-001 (NCT01295827), KEYNOTE-010 (NCT01905657), KEYNOTE-024 (NCT02142738), and KEYNOTE-042 (NCT02220894). Patients received pembrolizumab (2 mg/kg, 10 mg/kg, or 200 mg every 3 wk or 10 mg/kg every 2 wk); chemotherapy was a comparator in all studies except KEYNOTE-001. All studies included patients with previously treated, stable brain metastases.ResultsA total of 3170 patients were included, 293 (9.2%) with and 2877 (90.8%) without baseline brain metastases; median (range) follow-up at data cutoff was 12.9 (0.1‒43.7) months. Pembrolizumab improved overall survival versus chemotherapy in patients with or without baseline brain metastases: benefit was seen in patients with PD-L1 TPS ≥50% (0.67 [95% confidence intervals (CI): 0.44‒1.02] and 0.66 [95% CI: 0.58‒0.76], respectively) and PD-L1 TPS ≥1% (0.83 [95% CI: 0.62‒1.10] and 0.78 [95% CI: 0.71‒0.85], respectively). Progression-free survival was improved, objective response rates were higher, and duration of response was longer with pembrolizumab versus chemotherapy regardless of brain metastasis status. The incidence of treatment-related adverse events with pembrolizumab versus chemotherapy was 66.3% versus 84.4% in patients with brain metastases and 67.2% versus 88.3% in those without.ConclusionsPembrolizumab monotherapy improved outcomes and was associated with fewer adverse events than chemotherapy in patients with treatment-naive and previously treated PD-L1‒positive advanced/metastatic NSCLC regardless of the presence of baseline treated, stable brain metastases." @default.
• W3175514092 created "2021-07-05" @default.
• W3175514092 creator A5001428569 @default.
• W3175514092 creator A5004864286 @default.
• W3175514092 creator A5008593691 @default.
• W3175514092 creator A5009971196 @default.
• W3175514092 creator A5010668788 @default.
• W3175514092 creator A5016978421 @default.
• W3175514092 creator A5034276209 @default.
• W3175514092 creator A5034912444 @default.
• W3175514092 creator A5046728958 @default.
• W3175514092 creator A5055635838 @default.
• W3175514092 creator A5059513209 @default.
• W3175514092 creator A5060287300 @default.
• W3175514092 creator A5070079018 @default.
• W3175514092 creator A5071440718 @default.
• W3175514092 creator A5078402710 @default.
• W3175514092 creator A5085449385 @default.
• W3175514092 creator A5089150005 @default.
• W3175514092 date "2021-08-01" @default.
• W3175514092 modified "2023-10-17" @default.
• W3175514092 title "Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042" @default.
• W3175514092 cites W1982488143 @default.
• W3175514092 cites W2019607817 @default.
• W3175514092 cites W2104347254 @default.
• W3175514092 cites W2156353875 @default.
• W3175514092 cites W2198093519 @default.
• W3175514092 cites W2416791964 @default.
• W3175514092 cites W2493219106 @default.
• W3175514092 cites W2527905628 @default.
• W3175514092 cites W2560367415 @default.
• W3175514092 cites W2567564314 @default.
• W3175514092 cites W2572174216 @default.
• W3175514092 cites W2635951006 @default.
• W3175514092 cites W2753529762 @default.
• W3175514092 cites W2796086507 @default.
• W3175514092 cites W2807965874 @default.
• W3175514092 cites W2887050785 @default.
• W3175514092 cites W2905870269 @default.
• W3175514092 cites W2908622615 @default.
• W3175514092 cites W2912571746 @default.
• W3175514092 cites W2939283308 @default.
• W3175514092 cites W2959191827 @default.
• W3175514092 cites W2977319041 @default.
• W3175514092 cites W3000489007 @default.
• W3175514092 cites W3014209163 @default.
• W3175514092 cites W3100581984 @default.
• W3175514092 cites W3178873995 @default.
• W3175514092 doi "https://doi.org/10.1016/j.jtocrr.2021.100205" @default.
• W3175514092 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8474394" @default.
• W3175514092 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34590048" @default.
• W3175514092 hasPublicationYear "2021" @default.
• W3175514092 type Work @default.
• W3175514092 sameAs 3175514092 @default.
• W3175514092 citedByCount "29" @default.
• W3175514092 countsByYear W31755140922021 @default.
• W3175514092 countsByYear W31755140922022 @default.
• W3175514092 countsByYear W31755140922023 @default.
• W3175514092 crossrefType "journal-article" @default.
• W3175514092 hasAuthorship W3175514092A5001428569 @default.
• W3175514092 hasAuthorship W3175514092A5004864286 @default.
• W3175514092 hasAuthorship W3175514092A5008593691 @default.
• W3175514092 hasAuthorship W3175514092A5009971196 @default.
• W3175514092 hasAuthorship W3175514092A5010668788 @default.
• W3175514092 hasAuthorship W3175514092A5016978421 @default.
• W3175514092 hasAuthorship W3175514092A5034276209 @default.
• W3175514092 hasAuthorship W3175514092A5034912444 @default.
• W3175514092 hasAuthorship W3175514092A5046728958 @default.
• W3175514092 hasAuthorship W3175514092A5055635838 @default.
• W3175514092 hasAuthorship W3175514092A5059513209 @default.
• W3175514092 hasAuthorship W3175514092A5060287300 @default.
• W3175514092 hasAuthorship W3175514092A5070079018 @default.
• W3175514092 hasAuthorship W3175514092A5071440718 @default.
• W3175514092 hasAuthorship W3175514092A5078402710 @default.
• W3175514092 hasAuthorship W3175514092A5085449385 @default.
• W3175514092 hasAuthorship W3175514092A5089150005 @default.
• W3175514092 hasBestOaLocation W31755140921 @default.
• W3175514092 hasConcept C121608353 @default.
• W3175514092 hasConcept C126322002 @default.
• W3175514092 hasConcept C143998085 @default.
• W3175514092 hasConcept C197934379 @default.
• W3175514092 hasConcept C2776256026 @default.
• W3175514092 hasConcept C2776694085 @default.
• W3175514092 hasConcept C2777701055 @default.
• W3175514092 hasConcept C2778164965 @default.
• W3175514092 hasConcept C2779013556 @default.
• W3175514092 hasConcept C2780057760 @default.
• W3175514092 hasConcept C44249647 @default.
• W3175514092 hasConcept C71924100 @default.
• W3175514092 hasConceptScore W3175514092C121608353 @default.
• W3175514092 hasConceptScore W3175514092C126322002 @default.
• W3175514092 hasConceptScore W3175514092C143998085 @default.
• W3175514092 hasConceptScore W3175514092C197934379 @default.
• W3175514092 hasConceptScore W3175514092C2776256026 @default.
• W3175514092 hasConceptScore W3175514092C2776694085 @default.
• W3175514092 hasConceptScore W3175514092C2777701055 @default.
• W3175514092 hasConceptScore W3175514092C2778164965 @default.
• W3175514092 hasConceptScore W3175514092C2779013556 @default.

• next